ImmunityBio (IBRX) stock plunged nearly 25% after the FDA issued a warning letter regarding the promotion of its bladder cancer drug ANKTIVA. The regulator flagged claims by founder Patrick Soon-Shiong as misleading, specifically that the treatment could "cure and prevent all cancer." The FDA demanded corrections within 15 days or face legal action.